The global challenge of HIV/AIDS remains one of the most pressing public health issues today. According to the latest data from UNAIDS, around 38.4 million people worldwide are living with HIV/AIDS, underlining the need for not only medical intervention but also comprehensive awareness, education, and social change. Despite the significant strides made in treatment and prevention, the confusion surrounding the relationship between HIV and AIDS still persists.

Young people have become influential advocates in the fight against HIV/AIDS. Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities. These young activists utilize digital platforms and peer-to-peer education to dispel myths, promote safe practices, and foster supportive environments for those affected by HIV/AIDS.

Dr Gowri Kulkarni, an expert in Internal Medicine, explains that while the terms HIV and AIDS are often used interchangeably, they are distinctly different. "HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, whereas AIDS (Acquired Immunodeficiency Syndrome) is a condition that occurs when HIV severely damages the immune system," she clarifies. To understand the implications of these differences, it's important to explore the fundamental distinctions between the two.

1. HIV is a Virus; AIDS is a Syndrome

HIV is the virus responsible for attacking the body’s immune system, specifically targeting CD4 cells, which are crucial for the body’s defense against infections. As HIV progresses, it destroys these cells, weakening the immune system over time. If left untreated, this continuous damage can lead to AIDS.

AIDS, on the other hand, is a syndrome, not a virus. Dr Kulkarni further elaborates that AIDS is a collection of symptoms and illnesses that emerge when the immune system is severely compromised due to prolonged HIV infection. It represents the most advanced stage of HIV, and is characterized by very low CD4 counts or the onset of opportunistic infections like tuberculosis, pneumonia, or certain cancers.

2. Not Everyone with HIV Develops AIDS

A key distinction to remember is that not everyone with HIV will progress to AIDS. Thanks to advancements in medicine, particularly antiretroviral therapy (ART), individuals living with HIV can manage the virus and maintain a healthy immune system for many years, or even decades, without ever developing AIDS. ART works by suppressing the virus to undetectable levels, effectively preventing the damage HIV would otherwise cause to the immune system.

Without treatment, however, HIV progresses through three stages:

- Acute HIV Infection: This stage occurs shortly after transmission and may include symptoms like fever, fatigue, and swollen lymph nodes.

- Chronic HIV Infection: Often asymptomatic or mildly symptomatic, the virus continues to damage the immune system but at a slower rate.

- AIDS: This is the final stage, marked by severe immune damage and the presence of infections that take advantage of the compromised immune defenses.

3. HIV is Transmissible; AIDS is Not

Another key distinction between HIV and AIDS is the way in which they are transmitted. HIV is highly contagious and can be transmitted through the exchange of bodily fluids such as blood, semen, vaginal fluids, and breast milk. It is primarily spread through unprotected sexual contact, sharing needles, or from mother to child during childbirth or breastfeeding.

AIDS, however, is not transmissible. It is not a disease that can be passed from one person to another. Rather, AIDS is the result of untreated, advanced HIV infection and is a direct consequence of the virus’s damage to the immune system.

4. Diagnosis Methods Differ

HIV and AIDS are diagnosed through different methods. HIV is diagnosed through blood tests or oral swabs that detect the presence of the virus or antibodies produced by the immune system in response to the virus. Early detection of HIV is crucial, as it allows for timely intervention and treatment, which can prevent the virus from progressing to AIDS.

AIDS, on the other hand, is diagnosed using more specific criteria. Dr Kulkarni notes that the diagnosis of AIDS is made when the individual’s CD4 cell count falls below 200 cells/mm³, or when opportunistic infections or certain cancers (such as Kaposi's sarcoma or lymphoma) are detected. Diagnosing AIDS involves a more thorough assessment of the individual’s immune function and overall health, as opposed to just the detection of HIV.

5. Treatment Goals Are Different

The treatment goals for HIV and AIDS differ significantly, although both involve antiretroviral therapy (ART). For HIV, the primary treatment goal is to suppress the virus to undetectable levels, thus maintaining a strong immune system and preventing further transmission of the virus. People living with HIV can often live long, healthy lives if they adhere to ART.

For individuals diagnosed with AIDS, the treatment plan becomes more complex. While ART remains an essential part of managing the virus, treatment for AIDS also focuses on addressing the opportunistic infections and secondary health complications associated with severe immune suppression. The goal of treatment for AIDS is not only to manage the HIV virus but also to improve the quality of life and extend survival by treating these secondary health issues.

Role of Community Engagement in Combatting HIV/AIDS

While the medical community has made great strides in managing HIV, the battle to curb its transmission is also a social and cultural issue. Dr Daman Ahuja, a public health expert, highlights that HIV/AIDS awareness and education are vital to reducing transmission rates and supporting those affected by the virus. "Young people, especially, have become key advocates in the fight against HIV/AIDS," says Dr Ahuja. "Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities."

Additionally, grassroots activism plays a significant role in raising awareness and addressing stigma. As the World Health Organization reports, community-based interventions have been proven to increase HIV testing rates and improve treatment adherence, which are crucial in the fight against the pandemic.

The ultimate goal of organizations like UNAIDS is to eliminate the HIV/AIDS pandemic by 2030. Achieving this requires global collaboration, from medical treatment advancements to public health strategies, education, and advocacy. Dr Kulkarni’s insight underscores the importance of early detection, treatment adherence, and community support in the fight against HIV/AIDS.

Dr Gowri Kulkarni is Head of Medical Operations at MediBuddy and Dr Daman Ahuja, a public health expert and has been associated with Red Ribbon Express Project of NACO between 2007-12.

From physical problems like fatigue and vision problems, people who survive the deadly bacterial meningitis are likely to live with long-term fatigue and vision problems, as well as be at high risk of suicide, according to a new study.

The study comes as the UK is experiencing an outbreak of meningitis in Kent, that began among students who visited Club Chemistry in Canterbury between March 5 and 7.

Although bacterial meningitis is treatable, it requires prompt, often immediate treatment for better recovery. Yet patients are likely to face the risk of fatal or long-term complications -- from physical, psychological, and social impacts, said researchers from the University of Otago, The Conversation reported.

The new findings, based on 16 cases from New Zealand, who reportedly suffered the fatal disease, showed that multiple chronic after-effects is permanent in some, while in others, it dragged on for years. The effects include:

• fatigue,
• difficulties with concentration,
• memory and emotional regulation,
• persistent headaches,
• issues with mobility, vision, and hearing.

• anxiety,
• depression
• suicidality.

"Our findings demonstrate that bacterial meningitis is much more than a life-threatening infection. It is an acute disease with serious, chronic after-effects which are poorly understood and often go unrecognised," the researchers said.

Kent Meningitis Outbreak

The bug that causes the infection has been identified as the known strain of meningitis B, and MenB vaccines will be offered to 5,000 students living in the University of Kent halls of residence in Canterbury.

Meanwhile, the UKHSA chief executive, Susan Hopkins, said the outbreak "looks like a super-spreader" event with "ongoing spread" through universities' halls of residence.

"There will have been some parties, particularly around this, so there will have been lots of social mixing. I can't yet say where the initial infection came from, how it's got into this cohort, and why it's created such an explosive amount of infections," she added.

As per Trish Mannes, UKHSA Regional Deputy Director for the South East, even after two doses, the MenB vaccine “does not protect against all strains of meningococcal disease, nor against all infections that can cause meningitis. It also does not prevent the bacteria from being carried and spread in the community”.

The UKHSA thus warned people to be aware of the signs and symptoms of invasive meningococcal disease, and to seek immediate medical attention if they or anyone they know develops these signs and symptoms.

Common symptoms include:

• rash
• sudden onset of high fever
• severe and worsening headache
• vomiting and diarrhea
• joint and muscle pain
• seizures.

Being tall can have its advantages, but a new genetic study linked height with significant health problems, such as a higher risk of developing heart disease and endometriosis throughout one's lifetime.

While genetics and environmental factors together influence a person’s height, the stature can also prove to be a risk factor for determining the risk of atrial fibrillation, which occurs when the heart quivers rapidly and erratically instead of beating regularly, said the researchers from the China Medical University Hospital in Taiwan.

“By integrating genetic data across multiple East Asian biobanks, we show that the genetics of stature is linked not only to growth-related traits but also to clinically relevant outcomes—most notably atrial fibrillation and endometriosis," said the team in the paper.

"These results suggest that stature-related polygenic scores could help improve early risk stratification in East Asian populations,” they added.

Also read: Woman Left Medically Infertile After Seven Surgeries For Endometriosis That She Did Not Have

Key Findings

The team led by Fuu-Jen Tsai conducted a large-scale genetic analysis on people of East Asian origin. They analyzed 120,000 Han Taiwanese individuals and compared them with 27,966 controls with familial short stature (FSS) -- a harmless condition where people are short due to inherited genetics -- to find genetic factors.

The study also linked a person’s height to overall body size and lung function, as well as cardiovascular traits and reproductive traits, including the age when menstruation starts.

Their findings, published in the journal PLOS Genetics, identified 293 genetic variants linked to height and five linked to familial short stature.

The genetic variants responsible for tall stature increased the risks of both atrial fibrillation and endometriosis. In comparison, the genetic factors for short statures offered a slight protection against endometriosis.

The results proved that taller stature increased the risk of atrial fibrillation independently. But the risk of endometriosis was determined through menarche/weight in taller people.

The Role Of Estrogen

A 2020 study from Denmark shares a possible explanation for the link between height and increased risk of atrial fibrillation: the rising estrogen levels.

Estrogen is a hormone known to promote the growth of the lining of the womb and is also believed to play a role in growth spurts during puberty.

The study, published in the Annals of Human Biology, showed that taller and slim girls in childhood had a high risk of developing endometriosis. The study also marked a lower body mass index as an increased risk of endometriosis.

However, further research is needed to validate these associations and inform clinical applications.

Early monitoring among younger populations has been the primary focus of the recently released American Heart Association (AHA) 2026 cholesterol guidelines.

The deliberate shift is reportedly based on new evidence about how heart disease develops over time.

Speaking exclusively to HealthandMe, Dr. Nils P Johnson, Professor of Cardiology, University of Texas, Houston, US, shared that atherosclerosis, or the buildup of plaque in arteries, doesn’t suddenly appear in middle age; it begins silently in youth.

That is why the AHA guidelines highlighted the importance of early screening.

“Cholesterol risk is really about long-term exposure. Just like years of breathing polluted air can damage your lungs, cholesterol builds up in the body over time. It’s not just about how high your levels are at one moment—it’s about how long you’ve lived with them. For example, one person might have very high cholesterol for 30–40 years, while another has moderately elevated levels for 60 years. Over time, their total exposure can be similar—and so can their risk," Dr. Johnson said.

What this means in practice is that treating cholesterol is about reducing total lifetime exposure.

The cardiologist explained that there are two ways to do that: lower cholesterol levels or start treatment earlier.

"Both approaches achieve the same goal—shrinking the overall ‘cholesterol burden’ by reducing how much cholesterol is in the body and how long a person is exposed to it,” the expert said.

The AHA 2026 Cholesterol Guidelines

As per the Global Burden of Disease Study 2021, the burden of heart failure in adolescents and young adults aged 10–24 years is increasing globally.

The guidelines call for early intervention through early screening and healthy lifestyle changes, starting from childhood.

It recommends:

• Children (9-11 years): Cholesterol screening if never done before.
• Adults (30-79 years): Evaluate 10- and 30-year ASCVD risk to determine the need for early intervention
• Considering lipid-lowering therapy for young adults with -- persistent LDL of at least 160 mg/dL, strong family history of ASCVD, and/or at least 10 percent 30-year risk for ASCVD

"They encourage us to think beyond the usual 5- or 10-year risk window and consider the long-term picture—what might happen 20 or 30 years down the road for someone in their 40s or 50s,” Dr. Johnson told HealthandMe.

Also read: ACC/AHA Cholesterol Guidelines 2026 Explained: Start Screening For Cardiovascular Diseases Early

Heart Disease: A Long-term Treatment

The heart expert also stated that chronic conditions like heart disease require long-term management—sometimes for decades—unlike an infection, where a two-week antibiotic course resolves the problem.

“One of the biggest challenges I see in clinics is that patients often come in after a dramatic event—chest pain, a heart attack, or a procedure. Alongside immediate treatment, I prescribe medications and recommend lifestyle changes. And then patients ask, ‘How long do I have to do this? This reflects a very different mindset”.

Dr. Johnson urged cardiologists and other healthcare workers to help patients understand, accept, and sustain these changes over the long term.

“Adjusting to the reality that life will be different for years or even a lifetime is not easy, but it’s essential,” he said.